Study S000477

The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00856609
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 150
Start: 2009-03-03
Primary completion: 2016-09-19
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions: Weight Loss; Obesity
Interventions: DRUG:Byetta (exenatide); BEHAVIORAL:Weight loss; OTHER:Metabolic Chamber; DRUG:Placebo
Results posted: TRUE
Secondary identifiers: OTHER:09-DK-N095

Registered primary outcomes

Energy Intake [Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention)]
Twenty-four-hour Energy Expenditure [Day 5 and Day 11]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024940	Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. Basolo A, Metabolism: clinical and experimental	2018	Randomized trial	PMID 29596853 DOI	cites ClinicalTrials.gov:NCT00856609; registry reference DERIVED:29596853
R0023824	Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE, JAMA	2007	Systematic review	PMID 17622601 DOI	registry reference BACKGROUND:17622601
R0026490	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Buse JB, Clinical therapeutics	2007	Randomized trial	PMID 17379054 DOI	registry reference BACKGROUND:17379054
R0022827	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Buse JB, Diabetes care	2004	Randomized trial	PMID 15504997 DOI	registry reference BACKGROUND:15504997